Journal article
ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response
JA Holmes, SK Roberts, RJ Ali, GJ Dore, W Sievert, GW Mccaughan, DH Crawford, WS Cheng, MD Weltman, S Bonanzinga, K Visvanathan, V Sundararajan, PV Desmond, DS Bowden, GV Matthews, AJ Thompson
Hepatology | Published : 2014
DOI: 10.1002/hep.27022
Abstract
On-treatment anemia is associated with higher sustained virological response (SVR) rates during peginterferon plus ribavirin (RBV) therapy. Inosine triphosphatase (ITPA) variants causing ITPase deficiency have been shown to protect against RBV-induced anemia. However, ITPase activity has not been associated with SVR. To study this discrepancy, we examined the relationships between ITPase activity, on-treatment anemia, SVR, and RBV levels in hepatitis C virus genotype 1 (HCV-1) patients from the CHARIOT study. ITPA genotype (rs7270101, rs1127354) was used to define ITPase activity in 546 patients. Plasma RBV levels were measured using high-performance liquid chromatography (HPLC). Relationshi..
View full abstractGrants
Funding Acknowledgements
AJT and GM are supported by Career Development Fellowships from the National Health and Medical Research Council of Australia (NHMRC). The study was supported by a research grant from Roche Products, Pty, Limited (Australia).